New treatment plan for optic pathway glioma in children
Treatments studied
Part of Brain & nervous system, Cancer, Eyes & vision clinical trials.
This Phase 2 trial tests a modified chemotherapy treatment plan for children and young people with optic pathway glioma, aiming to shrink tumor and improve eye/brain symptoms. You may be able to join if your diagnosis is confirmed and your body can safely handle treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 3 months and 21 years old
- Your optic pathway glioma diagnosis was confirmed by tissue test or by MRI plus typical symptoms
- Your tumor can be measured on scans, or there is enough leftover tumor after surgery (not fully removed)
- Your overall function is good enough: KPS score ≥50 (if over 12) or Lansky score ≥50 (if 12 or younger)
- You have symptoms related to the tumor, such as vision changes or eye swelling or signs of increased pressure in the head
- Your main organs (heart, liver, kidneys, etc.) are working well enough for treatment
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 study tests whether adding recombinant human endostatin to temozolomide and irinotecan can slow or control recurrent gliomas (brain tumors) after prior standard treatment. It may help by targeting tumor blood vessel growth while also using chemotherapy to attack cancer cells.
This trial tests whether a new oral drug called FCN-159 works better than standard chemotherapy for children and teens with a slow-growing brain tumor (low-grade glioma) that has a specific change in the BRAF gene. The goal is to see if FCN-159 can shrink the tumor or stop it from growing.
This Phase 2 trial studies WVI for children and young adults with a newly diagnosed germ cell tumor in one side of the basal ganglia/thalamus. It aims to see how well the treatment works for tumors without spread within the brain.
This Phase 1/2 trial tests a study treatment for children and young adults under 22 whose brain glioma has come back or isn’t responding to prior treatment. It’s designed to see whether the treatment is safe and effective for shrinking tumors in this situation.
This Phase 2 trial studies whether a targeted medicine that blocks MEK can work better than chemotherapy for certain slow-growing brain tumors in children. You may qualify if your tumor has specific genetic features and has not already been treated with non-surgery therapies.
This trial tests a new drug called ADI-PEG 20 combined with standard treatments (temozolomide and radiation) for children and young adults with newly diagnosed high-grade glioma. It aims to see if this combination is safe and effective.
Hear when a new Optic Glioma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.